Download PDF
Thromb Haemost 1970; 23(03): 477-485
DOI: 10.1055/s-0038-1654074
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Quantitation of the Coagulation Inhibition in Vivo Due to Breakdown Products of Fibrin

P. S Mitchell   *
1   Department of Obstetrics and Gynecology New York university School of Medicine New York, New York
,
F. K Beller M. D.   **
1   Department of Obstetrics and Gynecology New York university School of Medicine New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Degradation products of human fibrinogen were prepared by in vitro lysis of fibrin clots by urokinase activation and injected into rabbits on a quantitative basis. The dose necessary to anticoagulate the animal was equal to 2½ to 3 times the animals’ fibrinogen level. The effect on whole blood clotting time and thrombin time lasted for approximately 2 hrs. The “r” time of the TEG returned to normal after 1 hr while the “Max” value remained abnormal for more than 120 min. Degradation product E was shown to clear more rapidly than D by immunochemical techniques. The overall T ½ clearance was found to be approximately 12 hrs.

* The data are part of the thesis for the completion of the Masters of Science Degree.


** Career Investigator of the City of New York (1-297).


 

  • References

  • 1 Triantaphyllopoulos D. C. Effects of intravenous injections of the anti-coagulant fraction of incubated fibrinogen on blood coagulation. Canad. J. Biochem 38: 909 1960;
    PubMedGoogle Scholar
  • 2 Lewis J. H, Wilson J. H. Fibrinogen breakdown products. Amer. J. Physiol 209: 1053 1965;
    PubMedGoogle Scholar
  • 3 Better F. K, Moki M. Properties of fibrinogenolysis and fibrinolysis products in immune assays. Thrombos. Diathes. haemorrh. (Stuttg.) 18: 114 1967;
    PubMedGoogle Scholar
  • 4 Rodriguez-Erdmann F. Über eine einfache Methode zur wiederholten Blutgewinnung beim Kaninchen. Pflügers Arch. ges. Physiol 269: 306 1959;
    CrossrefPubMedGoogle Scholar
  • 5 Astrup T, Glas P, Kok P. Assay of the plasminogen activator intissues. (In press, 1968).
    PubMedGoogle Scholar
  • 6 Marchai G, Leroux M. E, Semama M. Atlas de Thrombodynamographie. Service de Propogande Edition. 1959
    PubMedGoogle Scholar
  • 7 Godai H. C, Helle I. The influence of flbrinogenolytic and fibrinolytic split products on the last stage of coagulation. Scand. J. clin. Lab. Invest 15: 327 1963;
    CrossrefPubMedGoogle Scholar
  • 8 Schulz F. H. Eine einfache Bewertungsmethode von Leberparenchymschäden (volumetri-sche Fibrinbestimmung). Actahepat. (Hamburg) 3: 306 1955;
    PubMedGoogle Scholar
  • 9 Ratnoff O. D, Menzi O. Estimation of fibrinogen in small samples of plasma. Blood Coagulation, Hemorrhage and Thrombosis. 224 Tocantins L. M, Kazal L. A. eds. Grune & Stratton; New York: 1964
    Google Scholar
  • 10 McKay G. G. Practical application of Immunoelectrophoresis. Lab. Synopsis 2:1. Hoechst Pharmaceutical Co.; Kansas City, Mo.: 1967
    Google Scholar
  • 11 Mancini G, Vaerman J. P, Carbonara A. O, Heremans J. F. Simple Radial Immunodiffusion. Lab. Synopsis 1: 43. Lloyd Bros. Inc.; Cincinnati, Ohio: 1965
    Google Scholar
  • 12 Hill B. A. Principles of Medical Statistics. Oxford University Press; New York: 1961
    Google Scholar
  • 13 Nussenzweig V, Seligmann M, Grabar P. Les Products De Degradation Du Fibrinogene Humain Par La Plasmine. Ann. Inst. Pasteur 100: 377 1961;
    PubMedGoogle Scholar
  • 14 Larrieu M. J, Marder V. J, Onceman S. Effects of fibrinogen degradation products on platelets and coagulation. Diffuse intravascular clotting. Trans, of the conf. of the Internat. Comm. on Hemostasis and Thrombosis. F. K. Schattauer; Stuttgart: 1966
    Google Scholar
  • 15 Fletcher A. P, Alkjaersig N, Fisher S, Sherry S. The proteolysis of fibrinogen by plasmin. The identification of thrombin clottable fibrinogen derivatives which polymerize abnormally. J. Lab. clin. Med 68 (03) 780 1966;
    PubMedGoogle Scholar
  • 16 Niewiarowski S, Kowalski E. Un Nouvel anticoagulant derive die fibrinogène. Rev. Hémat 13: 320 1958;
    PubMedGoogle Scholar
  • 17 Triantaphyllopoidos D. C. Anticoagulant effect of incubated fibrinogen. Canad. J. Biochem 36: 248 1958;
    PubMedGoogle Scholar
  • 18 Bang N. U. Normal and abnormal fibrin polymerization. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl 13: 131 1963;
    PubMedGoogle Scholar
  • 19 Wilson P. A, McNicol G. P, Douglas A. S. Effect of Fibrinogen degradation products on platelet aggregation. J. clin. Pathol 21: 147 1968;
    CrossrefPubMedGoogle Scholar
  • 20 Fletcher A. P, Alkjaersig N, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. clin. Invest 41: 896 1962;
    CrossrefPubMedGoogle Scholar
  • 21 Steichele D. F, Herrscheein H. J. Immunochemischer Nachweis von Fibrinogenderivaten im Urin bei Verbrauchskoagulopathien. Thrombos. Diathes. haemorrh. (Stuttg.) 19: 248 1968;
    PubMedGoogle Scholar